139 related articles for article (PubMed ID: 35218770)
1. Site-Specific Dinitrophenylation of Single-Chain Antibody Fragments for Redirecting a Universal CAR-T Cell against Cancer Antigens.
Rong L; Lim RM; Yin X; Tan L; Yang JH; Xie J
J Mol Biol; 2022 Apr; 434(8):167513. PubMed ID: 35218770
[TBL] [Abstract][Full Text] [Related]
2. Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.
Klesmith JR; Su L; Wu L; Schrack IA; Dufort FJ; Birt A; Ambrose C; Hackel BJ; Lobb RR; Rennert PD
Mol Pharm; 2019 Aug; 16(8):3544-3558. PubMed ID: 31242389
[TBL] [Abstract][Full Text] [Related]
3. Fully human antibody V
Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386
[TBL] [Abstract][Full Text] [Related]
4. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
[TBL] [Abstract][Full Text] [Related]
7. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
8. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
9. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.
Sutherland AR; Owens MN; Geyer CR
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007850
[TBL] [Abstract][Full Text] [Related]
10. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
11. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
13. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
14. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
[TBL] [Abstract][Full Text] [Related]
15. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
Front Immunol; 2021; 12():799206. PubMed ID: 34975912
[TBL] [Abstract][Full Text] [Related]
19. CAR T cell therapy.
Hosen N
Immunol Med; 2021 Jun; 44(2):69-73. PubMed ID: 32693699
[TBL] [Abstract][Full Text] [Related]
20. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]